The global vasopressin market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The growth of this market can be attributed to the increasing prevalence of cardiovascular diseases and other conditions that require vasopressin therapy.
Intravenous Injection segment is expected to dominate the global vasopressin market during the forecast period, owing to its high efficacy and easy administration route. Intramuscular Injection segment is expected to grow at a higher CAGR than intravenous injection segment due to its ease in administration and low cost. Subcutaneous Injection segment is also projected for significant growth due to its ease in administration and low cost as compared with intravenous injection. Antidiuretic Hormone Deficiency application segment dominated the global vasopressin market in 2017, followed by Vasodilatory Shock application segment which accounted for over 30% share of total revenue generated by this product type in 2017. Gastrointestinal Bleeding application was also projected for significant growth during the forecast period owing to increasing incidence rates of gastrointestinal bleeding across various regions globally.
- Vasopressin is a hormone that regulates water retention in the body.
- It is used to treat conditions such as diabetes insipidus, congestive heart failure, and cirrhosis of the liver.
- Vasopressin is also used to treat bleeding disorders such as Von Willebrand disease and hemophilia A or B by increasing blood clotting time and platelet aggregation.
- The drug has been approved for use in the United States since 1953.
- The drug was originally isolated from pituitary glands of cows.
Industry Growth Insights published a new data on “Vasopressin Market”. The research report is titled “Vasopressin Market research by Types (Intravenous Injection, Intramuscular Injection, Subcutaneous Injection), By Applications (Anti-Diuretic Hormone Deficiency, Vasodilatory Shock, Gastrointestinal Bleeding, Ventricular Tachycardia & Fibrillation), By Players/Companies Novartis, Pfizer, Fresenius Kabi Canada, Par Pharmaceutical, Ferring Pharmaceuticals, Astellas Pharma, Shanghai Soho-Yiming Pharmaceuticals”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Vasopressin Market Research Report
By Type
Intravenous Injection, Intramuscular Injection, Subcutaneous Injection
By Application
Anti-Diuretic Hormone Deficiency, Vasodilatory Shock, Gastrointestinal Bleeding, Ventricular Tachycardia & Fibrillation
By Companies
Novartis, Pfizer, Fresenius Kabi Canada, Par Pharmaceutical, Ferring Pharmaceuticals, Astellas Pharma, Shanghai Soho-Yiming Pharmaceuticals
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
246
Number of Tables & Figures
173
Customization Available
Yes, the report can be customized as per your need.
Global Vasopressin Market Report Segments:
The global Vasopressin market is segmented on the basis of:
Types
Intravenous Injection, Intramuscular Injection, Subcutaneous Injection
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Anti-Diuretic Hormone Deficiency, Vasodilatory Shock, Gastrointestinal Bleeding, Ventricular Tachycardia & Fibrillation
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novartis
- Pfizer
- Fresenius Kabi Canada
- Par Pharmaceutical
- Ferring Pharmaceuticals
- Astellas Pharma
- Shanghai Soho-Yiming Pharmaceuticals
Highlights of The Vasopressin Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Intravenous Injection
- Intramuscular Injection
- Subcutaneous Injection
- By Application:
- Anti-Diuretic Hormone Deficiency
- Vasodilatory Shock
- Gastrointestinal Bleeding
- Ventricular Tachycardia & Fibrillation
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Vasopressin Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Vasopressin is a hormone that regulates water and electrolyte balance in the body. It also helps to control blood pressure, heart rate, and other functions. Vasopressin is produced by the hypothalamus in the brain.
Some of the major players in the vasopressin market are Novartis, Pfizer, Fresenius Kabi Canada, Par Pharmaceutical, Ferring Pharmaceuticals, Astellas Pharma, Shanghai Soho-Yiming Pharmaceuticals.
The vasopressin market is expected to register a CAGR of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Vasopressin Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Vasopressin Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Vasopressin Market - Supply Chain
4.5. Global Vasopressin Market Forecast
4.5.1. Vasopressin Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Vasopressin Market Size (000 Units) and Y-o-Y Growth
4.5.3. Vasopressin Market Absolute $ Opportunity
5. Global Vasopressin Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Vasopressin Market Size and Volume Forecast by Type
5.3.1. Intravenous Injection
5.3.2. Intramuscular Injection
5.3.3. Subcutaneous Injection
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Vasopressin Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Vasopressin Market Size and Volume Forecast by Application
6.3.1. Anti-Diuretic Hormone Deficiency
6.3.2. Vasodilatory Shock
6.3.3. Gastrointestinal Bleeding
6.3.4. Ventricular Tachycardia & Fibrillation
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Vasopressin Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Vasopressin Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Vasopressin Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Vasopressin Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Vasopressin Demand Share Forecast, 2019-2026
9. North America Vasopressin Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Vasopressin Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Vasopressin Market Size and Volume Forecast by Application
9.4.1. Anti-Diuretic Hormone Deficiency
9.4.2. Vasodilatory Shock
9.4.3. Gastrointestinal Bleeding
9.4.4. Ventricular Tachycardia & Fibrillation
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Vasopressin Market Size and Volume Forecast by Type
9.7.1. Intravenous Injection
9.7.2. Intramuscular Injection
9.7.3. Subcutaneous Injection
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Vasopressin Demand Share Forecast, 2019-2026
10. Latin America Vasopressin Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Vasopressin Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Vasopressin Market Size and Volume Forecast by Application
10.4.1. Anti-Diuretic Hormone Deficiency
10.4.2. Vasodilatory Shock
10.4.3. Gastrointestinal Bleeding
10.4.4. Ventricular Tachycardia & Fibrillation
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Vasopressin Market Size and Volume Forecast by Type
10.7.1. Intravenous Injection
10.7.2. Intramuscular Injection
10.7.3. Subcutaneous Injection
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Vasopressin Demand Share Forecast, 2019-2026
11. Europe Vasopressin Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Vasopressin Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Vasopressin Market Size and Volume Forecast by Application
11.4.1. Anti-Diuretic Hormone Deficiency
11.4.2. Vasodilatory Shock
11.4.3. Gastrointestinal Bleeding
11.4.4. Ventricular Tachycardia & Fibrillation
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Vasopressin Market Size and Volume Forecast by Type
11.7.1. Intravenous Injection
11.7.2. Intramuscular Injection
11.7.3. Subcutaneous Injection
11.8. Basis Point Share (BPS) Analysis by Tye
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Vasopressin Demand Share, 2019-2026
12. Asia Pacific Vasopressin Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Vasopressin Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Vasopressin Market Size and Volume Forecast by Application
12.4.1. Anti-Diuretic Hormone Deficiency
12.4.2. Vasodilatory Shock
12.4.3. Gastrointestinal Bleeding
12.4.4. Ventricular Tachycardia & Fibrillation
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Vasopressin Market Size and Volume Forecast by Type
12.7.1. Intravenous Injection
12.7.2. Intramuscular Injection
12.7.3. Subcutaneous Injection
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Vasopressin Demand Share, 2019-2026
13. Middle East & Africa Vasopressin Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Vasopressin Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Vasopressin Market Size and Volume Forecast by Application
13.4.1. Anti-Diuretic Hormone Deficiency
13.4.2. Vasodilatory Shock
13.4.3. Gastrointestinal Bleeding
13.4.4. Ventricular Tachycardia & Fibrillation
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Vasopressin Market Size and Volume Forecast by Type
13.7.1. Intravenous Injection
13.7.2. Intramuscular Injection
13.7.3. Subcutaneous Injection
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Vasopressin Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Vasopressin Market: Market Share Analysis
14.2. Vasopressin Distributors and Customers
14.3. Vasopressin Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Novartis
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Pfizer
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Fresenius Kabi Canada
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Par Pharmaceutical
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Ferring Pharmaceuticals
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Astellas Pharma
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Shanghai Soho-Yiming Pharmaceuticals
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
